Cargando…

Antileukemic Effects of Anti-miR-146a, Anti-miR-155, Anti-miR-181a, and Prednisolone on Childhood Acute Lymphoblastic Leukemia

Prednisolone has been used frequently in the treatment of acute lymphoblastic leukemia. However, to overcome the challenges of the treatment, the development of additional therapies is of great importance. Small, non-protein-coding RNAs, namely, microRNAs (miRNAs), are critical epigenetic regulators...

Descripción completa

Detalles Bibliográficos
Autores principales: Durmaz, Burak, Bagca, Bakiye Goker, Cogulu, Ozgur, Susluer, Sunde Yilmaz, Alpay, Araz, Aksoylar, Serap, Gunduz, Cumhur
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8645370/
https://www.ncbi.nlm.nih.gov/pubmed/34877353
http://dx.doi.org/10.1155/2021/3207328
_version_ 1784610290149621760
author Durmaz, Burak
Bagca, Bakiye Goker
Cogulu, Ozgur
Susluer, Sunde Yilmaz
Alpay, Araz
Aksoylar, Serap
Gunduz, Cumhur
author_facet Durmaz, Burak
Bagca, Bakiye Goker
Cogulu, Ozgur
Susluer, Sunde Yilmaz
Alpay, Araz
Aksoylar, Serap
Gunduz, Cumhur
author_sort Durmaz, Burak
collection PubMed
description Prednisolone has been used frequently in the treatment of acute lymphoblastic leukemia. However, to overcome the challenges of the treatment, the development of additional therapies is of great importance. Small, non-protein-coding RNAs, namely, microRNAs (miRNAs), are critical epigenetic regulators with physiological and pathological importance. This study is aimed at determining the effects of miR-146a, miR-155, and miR-181a inhibition with their corresponding anti-miRs on both leukemic and healthy cells, individually and with prednisolone. Leukemic (SUP-B15) and healthy B-lymphocyte (NCI-BL 2171) cell lines were used in this study. A total of 12 experimental groups included individual and combinational silenced ALL-associated miRNAs (hsa-miR-155, hsa-miR-146a, and hsa-miR-181a) and their combination with prednisolone. Cytotoxicity, proliferation, cell cycle, and apoptosis analyses were performed by using WST-1, trypan blue, APC-BrdU, Annexin V, and JC-1 methods in each study group, respectively. To control the effectiveness of anti-miR transfection and prednisolone application, miRNA expression analysis was performed from all groups. Anti-miR application was effective on the viability, proliferation, cell cycle, and apoptosis of leukemia cells, and this effect was increased with prednisolone administration. In addition, this activity was found to be very low on healthy cells. In conclusion, anti-miR applications may have the potential for clinical use of adjuvant to or as an alternative to conventional therapies for childhood acute lymphoblastic leukemia.
format Online
Article
Text
id pubmed-8645370
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-86453702021-12-06 Antileukemic Effects of Anti-miR-146a, Anti-miR-155, Anti-miR-181a, and Prednisolone on Childhood Acute Lymphoblastic Leukemia Durmaz, Burak Bagca, Bakiye Goker Cogulu, Ozgur Susluer, Sunde Yilmaz Alpay, Araz Aksoylar, Serap Gunduz, Cumhur Biomed Res Int Research Article Prednisolone has been used frequently in the treatment of acute lymphoblastic leukemia. However, to overcome the challenges of the treatment, the development of additional therapies is of great importance. Small, non-protein-coding RNAs, namely, microRNAs (miRNAs), are critical epigenetic regulators with physiological and pathological importance. This study is aimed at determining the effects of miR-146a, miR-155, and miR-181a inhibition with their corresponding anti-miRs on both leukemic and healthy cells, individually and with prednisolone. Leukemic (SUP-B15) and healthy B-lymphocyte (NCI-BL 2171) cell lines were used in this study. A total of 12 experimental groups included individual and combinational silenced ALL-associated miRNAs (hsa-miR-155, hsa-miR-146a, and hsa-miR-181a) and their combination with prednisolone. Cytotoxicity, proliferation, cell cycle, and apoptosis analyses were performed by using WST-1, trypan blue, APC-BrdU, Annexin V, and JC-1 methods in each study group, respectively. To control the effectiveness of anti-miR transfection and prednisolone application, miRNA expression analysis was performed from all groups. Anti-miR application was effective on the viability, proliferation, cell cycle, and apoptosis of leukemia cells, and this effect was increased with prednisolone administration. In addition, this activity was found to be very low on healthy cells. In conclusion, anti-miR applications may have the potential for clinical use of adjuvant to or as an alternative to conventional therapies for childhood acute lymphoblastic leukemia. Hindawi 2021-11-28 /pmc/articles/PMC8645370/ /pubmed/34877353 http://dx.doi.org/10.1155/2021/3207328 Text en Copyright © 2021 Burak Durmaz et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Durmaz, Burak
Bagca, Bakiye Goker
Cogulu, Ozgur
Susluer, Sunde Yilmaz
Alpay, Araz
Aksoylar, Serap
Gunduz, Cumhur
Antileukemic Effects of Anti-miR-146a, Anti-miR-155, Anti-miR-181a, and Prednisolone on Childhood Acute Lymphoblastic Leukemia
title Antileukemic Effects of Anti-miR-146a, Anti-miR-155, Anti-miR-181a, and Prednisolone on Childhood Acute Lymphoblastic Leukemia
title_full Antileukemic Effects of Anti-miR-146a, Anti-miR-155, Anti-miR-181a, and Prednisolone on Childhood Acute Lymphoblastic Leukemia
title_fullStr Antileukemic Effects of Anti-miR-146a, Anti-miR-155, Anti-miR-181a, and Prednisolone on Childhood Acute Lymphoblastic Leukemia
title_full_unstemmed Antileukemic Effects of Anti-miR-146a, Anti-miR-155, Anti-miR-181a, and Prednisolone on Childhood Acute Lymphoblastic Leukemia
title_short Antileukemic Effects of Anti-miR-146a, Anti-miR-155, Anti-miR-181a, and Prednisolone on Childhood Acute Lymphoblastic Leukemia
title_sort antileukemic effects of anti-mir-146a, anti-mir-155, anti-mir-181a, and prednisolone on childhood acute lymphoblastic leukemia
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8645370/
https://www.ncbi.nlm.nih.gov/pubmed/34877353
http://dx.doi.org/10.1155/2021/3207328
work_keys_str_mv AT durmazburak antileukemiceffectsofantimir146aantimir155antimir181aandprednisoloneonchildhoodacutelymphoblasticleukemia
AT bagcabakiyegoker antileukemiceffectsofantimir146aantimir155antimir181aandprednisoloneonchildhoodacutelymphoblasticleukemia
AT coguluozgur antileukemiceffectsofantimir146aantimir155antimir181aandprednisoloneonchildhoodacutelymphoblasticleukemia
AT susluersundeyilmaz antileukemiceffectsofantimir146aantimir155antimir181aandprednisoloneonchildhoodacutelymphoblasticleukemia
AT alpayaraz antileukemiceffectsofantimir146aantimir155antimir181aandprednisoloneonchildhoodacutelymphoblasticleukemia
AT aksoylarserap antileukemiceffectsofantimir146aantimir155antimir181aandprednisoloneonchildhoodacutelymphoblasticleukemia
AT gunduzcumhur antileukemiceffectsofantimir146aantimir155antimir181aandprednisoloneonchildhoodacutelymphoblasticleukemia